BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CAL-101: Interim Phase I data

Interim data from an ongoing, open-label, U.S. Phase I trial in 18 evaluable patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) showed that twice-daily 100 or 150 mg oral CAL-101 in combination with rituximab or Treanda bendamustine produced an objective response rate (ORR) of 83%, with 1 complete...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >